Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DGPlex:
DNAG'S is "Ancestry by DNA" - NOT Ancestry.com. But, correct me if I'm wrong.
Take care,
Ann
DNAP on UTUBE:
You can get this Conference and Home on PDF format, but, it won't copy. Perhaps, during or after the conference.
Ann
Frudakis speaks from 8:30 to 10 a.m. on Fri., Oct. 26:
http://www.moffitt.usf.edu/Site.aspx?spid=AE7BB33B4D4D4733BCB3CBD039696AB2&Date=10%2f24%2f2007
Ann
1st Annual Total Care Conference:
http://www.moffitt.usf.edu/Site.aspx?spid=AE7BB33B4D4D4733BCB3CBD039696AB2&Date=10%2f24%2f2007
Ann
More on the book Tony Frudakis has published:
http://www.marketwire.com/mw/release.do?id=773757
Ann
DNAPrint enters neurotherapeutics collaboration
6th March 2006
By Staff Writer
DNAPrint Genomics has revealed that it is to collaborate with the Massachusetts College of Pharmacy and Health Sciences on the potential development of Ritalin-like compounds as possible medications for drug abuse, ADHD and depression.
The compounds are analogs of Novartis' Ritalin, used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.
The research will be conducted under the supervision of Dr Mark Froimowitz, a researcher at the Boston-based college, who recently licensed the compounds to DNAPrint Genomics.
"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," stated DNAPrint chief medical officer Dr Hector Gomez. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."
Ann
Looks like a new web site for Trace Genetics:
http://www.tracegenetics.com/custom.html
Ann
Tony Frudakis part of the Management Team at Genelex:
http://www.genelex.com/commonhtmls/companyprofile.html
Ann
A part of Richard Gabriel's credential history:
"He was instrumental in closing and managing more than
$135 million in contract revenue for Pharm-Eco Laboratories and
successfully completed the formation of numerous joint ventures, limited liability companies and spin-offs that resulted in several public and private companies in the genetics/chemistry/pharmaceutical field."
Ann
Richard Gabriel Interview on YouTube:
I entered DNAPrint on My Space. This is what came up:
http://profile.myspace.com/index.cfm?fuseaction=user.viewprofile&friendID=98538435
Ann
DNAP's African Ancestry from MySpace:
http://blog.myspace.com/index.cfm?fuseaction=blog.ListAll&friendID=96681549&MyToken=d94043bc...
Ann
Power_
Sorry - already brought up tonight. I came in late and didn't have time to read over all posts at the time I posted.
Take care,
Ann
Power:
"link says Scientists criticize Ancestry.com"
FYI - DNAP's is "Ancestry by DNA" & NOT Ancestry.com
Ann
DogHouse:
You're welcome. I wish us the best!
Take care,
Ann
DNAP Presentation at 1:35 p.m.
1:35 PM - 1:55 PM DNAprint Genomics, Inc. (DNAG)
Real Player | Windows Media
Ann
DNAP scheduled presentation:
http://www.visualwebcaster.com/ValueRich/42896/event.html
Ann
Testimonials:
http://www.ivaluerich.com/expo.php?section=testimonials
Ann
What the presentation fee includes:
http://www.ivaluerich.com/expo.php?section=packages
Ann
Small Cap Financial Expo:
http://www.ivaluerich.com/expo.php?section=event
Ann
Don't forget the New Orleans Conferene:
http://www.theiacpconference.org/exhibitor_list.cfm#D
Ann
Thank you, Stockhldr.
Ann
Stockhldr:
Quote.com - real time - shows DNAG closing at at .063.
AOL quote is .007. What is your source? Wonder who's right on?
Ann
Superbee:
OT:
I have a kitty named Dusty. They're wonderful! All they give is love! When people refer to animals as being spoiled - I tell them they're not spoiled - "they're loved!"
Take care,
Ann
Host Bankers:
http://www.ivaluerich.com/expo.php?section=bankers
Ann
Only the ValueRich Expo offers company officers non-stop one-on-one access to:
FUND MANAGERS
MONEY MANAGERS
INSTITUTIONAL INVESTORS
RESEARCH ANALYSTS
INVESTMENT BANKERS
Ann
These are the presenting companies:
http://www.ivaluerich.com/expo.php?section=companies
Ann
BioServe web site:
http://www.bioserve.com/
Ann
How does DNAPrint's technology work?
Mr. Gabriel: Our technology is based on single nucleotide polymorphisms (SNPs), commonly called 'snips.' Normal DNA screening may require the analysis of millions of base pairs of genes to detect biological patterns. DNAPrint's technology for targeting SNPs eliminates the need to screen irrelevant base pairs, saving time and money. Our technology is proprietary and we have filed more than a dozen applications for national and international patent protection. When we started out, we
had one of the first SNP machines ' a first-rate device that was
developed by Orchid. We actually had the beta version. We now have a newer version made by Beckman Instruments, which bought the manufacturing equipment from Orchid. The new machine is very accurate, about 99.99%. With this technology we can identify the 2,000 or so ancestry information markers in genes for our consumer and forensics products. Looking down the road toward pharmaceutical development, we think there is a need to understand how families are related, what a genealogy of a family could be, if there is a disease component in a
family and whether a new drug can be specifically formulated to meet their individual or group needs. Even though we have validated our DNAWITNESS technology with blind test studies through police and crime laboratories, we are looking toward certification from the American Society of Crime Laboratory Directors (ASCLD). We need to either qualify
for certification on our own or obtain it through acquisition. So we're currently looking at acquisitions in general ' not only for the purpose of obtaining ASCLD certification but we're also shopping for clinical laboratories that could enable us to do diagnostics for the FDA. We had been focused on an acquisition that we had to terminate, and we now have targeted a number of synergistic acquisition candidates we're looking at
that will add revenue to the company.
Ann
This conference is presented by The International Association of Chiefs of Police.
Ann
Following are the Sponsors of the conference:
http://www.theiacpconference.org/sponsorships.cfm
Ann
Posted by Jonyfiber 3/07:
Posted by: johnnyfiber
In reply to: A deleted message Date:3/15/2007 4:26:26 PM
Post #of 70978
I sent a request and received an e-mail from Designed Marketing. There were 2 pdf attachments. copy:
DNAPrint™ Genomics, Inc. (“DNAPrint”) develops and markets genetic testing products and services. The company’s scientists aim their research towards discovery of DNA analysis solutions to serve clients in Forensic Science, Genealogical Research, and Pharmaceutical development. DNAPrint™ Genomics, Inc. is a cutting edge company with innovative products and solutions that could make a profound impact on improving our health care and combating crime and terrorism around the world.
Improving health care: DNAPrint has a breakthrough product
that allows the patient to be tested prior to beginning the drug
treatment to determine whether that drug treatment will be effective for them based on their specific DNA. This company’s
breakthrough products could make the difference in life or
death in patient. Over 100,000 people die each year from
improper drug treatment. Imagine the demand for this company’s
products when physicians and patients demand DNAPrint’s
products as the new standard practice to optimize the
diagnosis and treatment of their illness. Combating crime and terrorism: Based on a single piece of DNA, DNAPrint can provide law enforcement detailed descriptions and drawings of the suspect. Their products provide “exclusion” capabilities for investigators, and can narrow a list of suspects from
thousands down to just a few.
Why Invest Now:
• Hunting for the right drug therapy; revolutionized by DNAPrint!
• Hunting for a serial killer; revolutionized by DNAPrint!
• Hundreds of billions of dollars spent on healthcare, and demand
for new services and products is skyrocketing. World-wide
spending for new tools in the fight against terrorism and crime is skyrocketing.
• Company’s current market value around $4 million, and
Analyst recently estimated this company’s market value at
over $30 million. A potential 700-800% jump in value!!!
As demand for a company’s products skyrocket, typically their sales and stock price also skyrocket. This is your chance to get in early stage just before the potential surge in demand, and The Street realizes the potential of this up and coming company.
Thanks for your input!
Ann
This page w/o a year ID - interesting how Orchid was entwined, (under contract?) w/DNAP:
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/12-14-2004/0002630779&...
Ann
2006 Letter to Shareholders:
Have not seen this:
February 7, 2006
To Our Shareholders,
It has been sometime since I have had the chance to communicate with you directly and I welcome the opportunity to share with you some exciting new developments in your Company.
Perhaps the most exciting recent news is our licensing agreement with Harvard University covering a diagnostic test devised at Dr. Halperin’s Laboratory for Translational Research (LTR) at Harvard Medical School to target early identification of the population at risk of developing vascular diabetic complications. I have had the privilege of knowing Dr. Halperin for many years and am pleased that our Company is working with him and his excellent laboratory team.
The statistics on diabetes and its complications are alarming. Obesity, one of the more strongly linked causative agents for the onset of diabetes, is accelerating at a rapid rate in our country and across the globe. In fact, healthcare economists are predicting a record increase in healthcare costs linked to diabetes. For information on the financial and personal cost of these disease, I recommend you read the article from the New York Times, Diabetes and Its Awful Toll Quietly Emerge as a Crisis, by N.R. Kleinfield, 1/9/2006. http://query.nytimes.com/gst/fullpage.html?sec=health&res=9907E2DA1F30F93AA35752C0A9609C8B63
According to the National Heart Lung and Kidney Institute of Health, treatment of diabetic complications consumes 10-15% of our nation’s annual over-all healthcare budget. Diabetes is the leading cause of renal transplants, blindness and leg amputations in the adult population and major risk factor for heart attack and stroke. As juvenile obesity rises, the number of children afflicted with diabetic type disorders also increases.
Dr. Halperin’s research team has discovered that CD59, a protein that regulates the complement system, is found in a characteristically modified form in plasma and urine of diabetic patients. We hope to advance this technology, coupled with our genetic ancestry work, into a clinical test for the early detection of diabetic complications. We believe that a test based on CD-59 can help doctors early enough to permit meaningful treatment for patients. Early treatment may also permit lifestyle changes, including diet and exercise resulting in potentially improved health and quality of life for the patient. Long term, we would like to develop therapeutics screened against a validated and approved set of human markers. These types of therapies may help delay or treat the devastating consequences of diabetes and its complications.
DNAPrint’s employees, scientists and management appreciate your support and will work diligently to earn your continued support for the future.
Richard Gabriel,
CEO and President
Insights into racial profiling...:
http://www.bioforensics.com/conference07/Racial_Identification/index.html
Ann
In '03 Gomez served in Senior Clinical Research at Merck, Pres. & CEO of Transcend Theraputics:
UTEK Corporation Appoints Hector Gomez, M.D., Ph.D., to Scientific Advisory Council
Business Wire, Nov 20, 2003
UTEK Corporation (AMEX:UTK) announced today that Hector J. Gomez, M.D., Ph.D., has joined UTEK's Scientific Advisory Council. Previously, Dr. Gomez served as a Senior Director of clinical research at Merck/MSDRL, Executive Director of Clinical Research at CIBA-GEIGY Corporation, VP of Medical Affairs at Vertex Pharmaceuticals and President and CEO of Transcend Therapeutics. Dr. Gomez is currently a Member of the Board of Directors of PRB Pharmaceuticals and Apollo Pharmaceuticals and is the Chairman of the Board of Directors of DNAprint Genomics.
Dr. Gomez has considerable experience in both the scientific and business aspects of clinical research, pharmacology and pharmacogenomics. His knowledge and experience should enhance UTEK's ability to evaluate innovative pharmacologically related technologies. Dr. Gomez received his M.D. from the National University of Colombia in 1963 and his Ph.D. in Pharmacology from Marquette University in 1968. He also received a degree in Clinical Pharmacology from Tulane University (1973).
Take care,
Ann
Here's some info:
"Dr. Gomez has over twenty years of experience in the biopharmaceutical industry and has managed the development of 10 marketed drugs, mostly in the cardiovascular area. Dr. Gomez has previously served as President and CEO of Transcend Therapeutics, Inc., CEO of Zengen, Inc., Vice President of Medical Affairs for Vertex Pharmaceuticals and as an Executive Director with Ciba-Geigy Corporation. From 1979 to 1988 Dr. Gomez was a Director and Senior Director at Merck/MSDRL Corporation. He currently serves as the Chairman of the Board of Directors of DNAPrint™ genomics, Inc., PRB Pharmaceuticals, Inc. and Asia Healthcare Ltd. Dr. Gomez received an M.D. from the National University of Colombia, a Ph.D. from Marquette University, and a Diploma in Clinical Pharmacology from Tulane University.
Ann
Sent: Tue 7/3/2007 3:55 AM
To: dnap
Subject: From an original investor
I would like to share something I posted in reply to a shareholder on Investor's Hub:
"I've always believed in Tony Frudakis' inherant capabilities, achievements, capabilities & support. Tony Frudakis is a unique, omni-talented man of science in the field of computational theranostics, who is focused on accomplishing his achievements & participation of technological challenges! Most fortunately, in my opinion, he seems inherently aware of the sensitivity of shareholder value & support, those that have stood steadfast behind him for so many years and, so, with dignity & gratitude, he perceives the need to reward the investors with fair & higher shareholder values, - an outlook which is rare these days especially for the "Pinks." He is a unique, high-thoroughput, talented professional, not to mention his great capabilities as a developer of cutting edge technologies. He comes across as someone who is sincere and dedicated at every turn of his scientific endeavors. His achievements are not only invasive in the technology of sciences, but venture to the utmost delivery of benefiting of people from every makeup of the world. I would cast my vote for Tony Frudakis for the Nobel Peace Prize at the drop of a hat and hope that someday he will be rewarded as the receipient of one of the greatest achievements to mankind! JMHO
Take care,
Ann
Would be nice if Tony saw it - lol
But, thanks for letting me take up your time!
Reply:
Hello Ann, thank you very much for your kind words. I assure you I will make sure Tony and the rest of the team see your email.
Thank you for your continued support.
Louise
Investor Relations
DNAPrint genomics, Inc.
V 941-366-3400
dnap@dnaprint.com
Ann
This is something I wrote to DNAP & received a reply to! Go DNAP!
& good luck to all!
Take care all,
Ann